1. Home
  2. BEN vs GH Comparison

BEN vs GH Comparison

Compare BEN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Resources Inc.

BEN

Franklin Resources Inc.

HOLD

Current Price

$27.09

Market Cap

14.5B

Sector

Finance

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$102.21

Market Cap

14.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEN
GH
Founded
1947
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.5B
14.8B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BEN
GH
Price
$27.09
$102.21
Analyst Decision
Hold
Strong Buy
Analyst Count
9
21
Target Price
$25.89
$102.81
AVG Volume (30 Days)
6.5M
2.0M
Earning Date
01-30-2026
02-19-2026
Dividend Yield
4.87%
N/A
EPS Growth
64.88
N/A
EPS
1.08
N/A
Revenue
$8,846,200,000.00
$902,569,000.00
Revenue This Year
N/A
$35.23
Revenue Next Year
$5.80
$27.38
P/E Ratio
$25.08
N/A
Revenue Growth
1.23
30.38
52 Week Low
$16.25
$34.88
52 Week High
$28.32
$120.74

Technical Indicators

Market Signals
Indicator
BEN
GH
Relative Strength Index (RSI) 57.40 42.58
Support Level $26.80 $100.26
Resistance Level $28.32 $107.69
Average True Range (ATR) 0.86 6.19
MACD 0.03 -1.26
Stochastic Oscillator 62.77 20.87

Price Performance

Historical Comparison
BEN
GH

About BEN Franklin Resources Inc.

Franklin Resources provides investment services for individual and institutional investors. At the end of July 2025, Franklin had $1.617 trillion in managed assets, composed primarily of equity (41%), fixed-income (27%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (5%). Distribution tends to be weighted between retail investors (56% of AUM) and institutional accounts (41%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 31% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: